Director Juan Jose Chacon Quiros of Establishment Labs Holdings Inc (NASDAQ:ESTA) sold 37,500 common shares on April 14, 2026, according to a newly filed SEC disclosure. The sale produced total proceeds of $2.45 million at an average price of $65.228 per share, with individual trade prices reported between $65.00 and $65.60.
The filing notes that the transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan. After the sale, Chacon Quiros retains direct ownership of 45,193 common shares and holds an indirect interest in 1,182,504 shares through Sariel Group Ltd.
Establishment Labs shares have climbed 121% over the past year and were trading at $64.51 at the time of reporting, with a market capitalization of $1.89 billion. InvestingPro analysis cited in the filing indicates the stock is currently overvalued relative to its Fair Value. The filing also points investors to a comprehensive Pro Research Report covering ESTA and more than 1,400 other U.S. equities for further analysis.
In company results disclosed for the fourth quarter of 2025, Establishment Labs posted an adjusted earnings per share of -$0.09, beating the consensus estimate of -$0.22. The beat represents a 59.09% positive surprise versus the projection. Revenue for the quarter came in at $64.6 million, exceeding expectations of $63.75 million.
Following the quarterly disclosure, Stephens raised its price target for Establishment Labs shares to $90 from $85 and maintained an Overweight rating. The analyst highlighted the company’s 45% year-over-year revenue growth and an expansion of gross margin to 70.5% as drivers of the upgraded outlook.
The company also announced that it has sold more than 5 million Motiva breast implant devices globally. That milestone follows an earlier disclosure three years prior that the business had reached 3 million devices sold, indicating an increase in device distribution over the intervening period.
The SEC filing and the company’s financials together provide a snapshot of both insider liquidity actions and operational progress. The director sale, conducted under an established 10b5-1 plan, occurred against a backdrop of improving top-line performance and margin expansion, as well as analyst optimism reflected in a higher price target.
Where coverage or deeper valuation work is desired, the referenced Pro Research Report for ESTA and a broad universe of U.S. equities is noted as available through InvestingPro.